Despite these beneficial effects of mTOR inhibition on cardiovascular health, mTORC1 inhibition can also cause dyslipidaemia, a common risk factor for atherosclerosis, through downregulation of hepatic LDLRs and stimulation of lipophagy, resulting in a respective increase in circulating levels of LDL-cholesterol and droplet-released lipids (86, 87), meaning that the overall contribution of mTOR to atherosclerotic risk is complex (88). Here, MTOR is linked to atherosclerosis.